Price$0.76-0.01 (-1.67%)
02:00 PM07:45 PM
News · 26 weeks35+14%
2026-04-192026-10-11
Mix2090d
- Insider8(40%)
- SEC Filings7(35%)
- Other2(10%)
- Leadership1(5%)
- Offering1(5%)
- Analyst1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by iBio Inc.4 - iBio, Inc. (0001420720) (Issuer)
- INSIDERSEC Form 4 filed by iBio Inc.4 - iBio, Inc. (0001420720) (Issuer)
- INSIDERSEC Form 4 filed by iBio Inc.4 - iBio, Inc. (0001420720) (Issuer)
- INSIDERSEC Form 4 filed by iBio Inc.4 - iBio, Inc. (0001420720) (Issuer)
- INSIDERSEC Form 4 filed by iBio Inc.4 - iBio, Inc. (0001420720) (Issuer)
- INSIDERSEC Form 4 filed by iBio Inc.4 - iBio, Inc. (0001420720) (Issuer)
- SECSEC Form 8-K filed by iBio Inc.8-K - iBio, Inc. (0001420720) (Filer)
- PRiBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 TherapyIn an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human trials of IBIO-610 in first half of 2027 SAN DIEGO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, highlighted preclinical body-composition data from its obese non-human primate (NHP) study evaluating IBIO-610, potentially a first-in-class Activin E antibody candidate, alone and in combination with semaglutide, a GLP-1 receptor agonist use
- ANALYSTH.C. Wainwright initiated coverage on iBio with a new price targetH.C. Wainwright initiated coverage of iBio with a rating of Buy and set a new price target of $7.00
- SECiBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - iBio, Inc. (0001420720) (Filer)
- SECSEC Form DEF 14A filed by iBio Inc.DEF 14A - iBio, Inc. (0001420720) (Filer)
- PRiBio to Participate in the 2026 Wells Fargo Annual Healthcare ConferenceSAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced that it will participate in the Wells Fargo 21st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston. Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief Scientific Officer of iBio, will participate in a fireside chat on Tuesday, September 8, at 4:30 p.m. ET. A livestream of the event can be accessed here, and a replay of the presentation webcast will be available on the Investor Relations section of the iBio website for 90 days
- SECSEC Form 10-K filed by iBio Inc.10-K - iBio, Inc. (0001420720) (Filer)
- SECiBio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - iBio, Inc. (0001420720) (Filer)
- PRiBio Reports Fiscal Year 2026 Financial Results and Provides Corporate UpdateSAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress. "Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition," said Martin Brenner, Ph.D
- SECSEC Form PRE 14A filed by iBio Inc.PRE 14A - iBio, Inc. (0001420720) (Filer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Carr Molly4 - iBio, Inc. (0001420720) (Issuer)
- INSIDERSEC Form 3 filed by new insider Carr Molly3 - iBio, Inc. (0001420720) (Issuer)
- SECiBio Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits8-K - iBio, Inc. (0001420720) (Filer)
- PRiBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical OfficerSAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced the appointment of Molly Carr, M.D., as Chief Medical Officer, further strengthening its executive leadership as the company advances its clinical-stage cardiometabolic pipeline. An experienced physician with over 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, Dr. Carr will lead the company’s global clinical strategy, medical affairs, and regulatory initiatives as it advances its pipeline toward late-stage developme
- SECiBio Inc. filed SEC Form 8-K: Shareholder Director Nominations, Other Events, Financial Statements and Exhibits8-K - iBio, Inc. (0001420720) (Filer)
- SECiBio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - iBio, Inc. (0001420720) (Filer)
- PRiBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP StudySingle-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove greater visceral and total fat loss while reducing lean mass loss by 73% versus semaglutide alone Full dataset to be presented at European Association for the Study of Diabetes (EASD) Annual Meeting SAN DIEGO, July 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced new preclinical data from its obese non-human primate (NHP) study evaluatin
- ANALYSTRaymond James initiated coverage on iBio with a new price targetRaymond James initiated coverage of iBio with a rating of Outperform and set a new price target of $5.00
- ANALYSTB. Riley Securities initiated coverage on iBio with a new price targetB. Riley Securities initiated coverage of iBio with a rating of Buy and set a new price target of $6.00
IBIO FAQ
6 questionsWhat does iBio Inc. do?
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical...Where does IBIO stock trade?
iBio Inc. (IBIO) is listed on AMEX.What sector and industry is IBIO in?
iBio Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about IBIO?
iBio Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy with a $700.00 price target on 2026-09-17. Recent price targets range from $150.00 to $700.00.What companies are similar to IBIO?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare IBIO side-by-side with any of them on Quantisnow.How can I track IBIO on Quantisnow?
Quantisnow aggregates iBio Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow IBIO to receive live email and push alerts on every new disclosure.